Alivus Life Sciences Ltd

Alivus Life Sciences Limited, established in Mumbai, India, in 2001, is a pharmaceutical company that handles the full spectrum of active pharmaceutical ingredient (API) operations, from initial development and meticulous production to widespread market distribution. Its comprehensive portfolio of APIs includes compounds like olmesartan, telmisartan, sitagliptin, zonisamide, rosuvastatin, and palbociclib, addressing a broad range of medical needs. These encompass treatments for cardiovascular conditions, neurological disorders, diabetes, digestive health issues, cancer, pain management, immunosuppression, respiratory and ophthalmological ailments, urological concerns, and anti-infective applications. The company boasts a significant global presence, exporting its products to diverse markets across India, Japan, Europe, and both North and Latin America. Beyond its own product lines, Alivus also provides specialized contract development and manufacturing (CDMO) solutions to a variety of multinational corporations and niche pharmaceutical firms. Formerly known as Glenmark Life Sciences Limited, the company transitioned to its current name in December 2024 and operates as a subsidiary of Nirma Limited.